
LNPs in Drug Delivery: Status Today and Future Trends





Objectivs

Lipid Nano Particles (LNPs) are a break-through in drug delivery of RNA for vaccination (COVID-19) and hepatocyte targeting (Onpattro). The course addresses the challenges and opportunities academic and industrial pharmaceutical research have to address in order to further profit from this revolution. Top experts in this field will review, the specific lipids and RNAs used in LNPs, the stabilization of LNPs by means of lyophilization, organ targeting of LNPs, beyond the liver (hepatocytes), the ongoing and future clinical use of LNPs and finally regulatory aspects of new lipid excipients in LNPs.

Moderators



PD Dr. Peter van Hoogevest PHARMANOVATION, Řheinfelden, DE

Peter van Hoogevest, is a pharmacist by training (Utrecht University in The Netherlands), who got his PhD degree in biochemistry 1984 at the Utrecht

University in The Netherlands. In 1994 he received the degree of Privatdozent (adjunct professor) in pharmacy at the University of Basel, Switzerland. From 2012 till 2021 he was Managing Director of the Phospholipid Research Center, Heidelberg and Head of the Scientific Department (including the Development Department) of Lipoid GmbH, Ludwigshafen am Rhein, Germany). He runs from 2021 on his own consulting business PHARMANOVATION, based in Rheinfelden (Baden), Germany.



6963

Date

Dr. Simon Geißler Merck Healthcare KGaA, Darmstadt, DE

Simon is pharmacist by training with a PhD in Pharmaceutical technology from Johannes Gutenberg - University Mainz, Germany. Since 2009,

he worked in different positions in pharmaceutical development at Merck KGaA, comprising preformulation, drug delivery and CMC development support for discovery and development stage projects of NCEs and NBEs.

Programme

Tuesday, 28 November 2023, 13:00 - 17:30 h (CET)

Welcome address

PD Dr. Peter van Hoogevest, PHARMANOVATION, Rheinfelden, DE and Dr. Simon Geissler, Merck Healthcare KGaA, Darmstadt, DE

Lipid Nanoparticle-mRNA Formulations and their Applications Dr. Aditi Metha, Merck Healthcare KGaA, Darmstadt, DE

Design and manufacture of therapeutic mRNA Dr. Philippe Challis, eTheRNA, Niel, BE

The important role of PEGylated lipids and their innovative alternatives

Dr. Andrea Engel, Evonik Corporation, Brimingham AL, USA

Stability of mRNA-LNPs: in use and on the shelf Prof. Dr. Daan Crommelin, emiritus, Utrecht University, NL

Limits and possibilities to use LNPs for drug/RNA targeting; Lessons learned from liposomes

Prof. Dr. Gert Storm, Utrecht University, NL

Towards personalized LNPs in the clinic', LNPs, compounding, cancer immune therapy, orphan diseases

Prof. Dr. Raymond Schiffelers, Utrecht Medical Centre, NL

Recent regulatory experience with lipid nanoparticle components

Dr. Eva Hemmrich, University Basel, CH

Discussion

This conference is kindly organised by the APV focus group Drug Delivery

LNPs in drug delivery: Status today and future trends

Online Seminar Registration fee

Industry 400,00 EUR Authority/University 200,00 EUR Course no. 50,00 EUR Students*

(free of VAT according to § 4,22 UStG)

* Limited places for full time students available; written evidence must be 28 November 2023 13:00 - 17:30 h (CET)

Registration

If you have decided on the APV seminar, you can easily register online. We will process your registration immediately and will be happy to help you if you have any questions.

To the seminar and online registration form: https://www.apv-mainz.de/en/seminare/events/

An invoice/registration confirmation will be sent to you by email after you have successfully registered online.

Registration: www.apv-mainz.de/seminare



Phone: 0049 6131 97 69 0 0049 6131 97 69 69 Fax: E-mail: apv@apv-mainz.de